Without an IPO, Rib-X Raises $67.5 Million In Venture Funding
This article was originally published in The Pink Sheet Daily
Executive Summary
Rib-X will use the venture infusion to try to replicate Phase IIb data that indicated superiority to vancomycin for its broad-spectrum fluoroquinolone antibiotic.